Holmium Nanoparticles: Preparation and In Vitro Characterization of a New Device for Radioablation of Solid Malignancies

Abstract

PurposeThe present study introduces the preparation and in vitro characterization of a nanoparticle device comprising holmium acetylacetonate for radioablation of unresectable solid malignancies.MethodsHoAcAc nanoparticles were prepared by dissolving holmium acetylacetonate in chloroform, followed by emulsification in an aqueous solution of a surfactant and evaporation of the solvent. The diameter, surface morphology, holmium content, and zeta potential were measured, and thermal behavior of the resulting particles was investigated. The stability of the particles was tested in HEPES buffer. The r2* relaxivity of protons and mass attenuation coefficient of the nanoparticles were determined. The particle diameter and surface morphology were studied after neutron activation.ResultsSpherical particles with a smooth surface and diameter of 78 ± 10 nm were obtained, and the particles were stable in buffer. Neutron irradiation did not damage the particles, and adequate amounts of activity were produced for nuclear imaging and radioablation of malignancies through intratumoral injections.ConclusionsThe present study demonstrates that HoAcAc nanoparticles were prepared using a solvent evaporation process. The particle diameter can easily be adapted and can be optimized for specific therapeutic applications and tumor types.

Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

“…The high density of these microparticles (3.2 g/cm 3 ), which on occasion resulted in particle settling after intracatheter administration, and the lack of photon emissions by 90 Y, which prevented quantitative imaging, led to the development of other neutron-activatable materials. Microparticles composed of lower-density polymers, including polylactic acid (5-7), alginate (8), and chitosan (9) containing 166 Ho, as well as nanosized carrier materials containing stable 165 Ho for subsequent neutron activation to 166 Ho (10)(11)(12), have also been reported. 166 Ho is an attractive radionuclide for radiotherapeutic applications.…”

Radiolabeled Nanoparticles in Nuclear Oncology

“…The great advantage of using Holmium as a contrast agent is the fact that it is a nuclide that can be used in MR, CT and SPECT imaging, as well as in therapeutic applications [97].…”

Iron Oxide Nanoradiomaterials: Combining Nanoscale Properties with Radioisotopes for Enhanced Molecular Imaging

“…The preparation of 166 Ho-labeled holmium acetylacetonate NPs could be achieved by neutron activation using neutron flux of 5 × 10 12 cm −2 s −1 during 60 minutes. In this case, specific activities of 12 MBq/mg could be achieved [ 160 ]. Because 166 Ho emits beta particles, the activated NPs were suggested as potential radiotherapeutic agents for the treatment of solid cancers.…”